Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies
- 413 Downloads
Background Pegfilgrastim is widely used for prophylaxis of febrile neutropenia (FN) in cancer patients receiving chemotherapies. However, the optimal timing of pegfilgrastim administration has not been established. Objective We investigated the effect of the timing of pegfilgrastim administration on the prevention of FN in patients with breast cancer undergoing intermediate-risk chemotherapies. Method We retrospectively analysed the incidence of FN in patients with breast cancer treated at our institution with intermediate-risk chemotherapies and primary or secondary prophylactic pegfilgrastim between 2015 and 2017. The impact of the timing of pegfilgrastim administration on the incidence of FN was evaluated by univariate and multivariate logistic regression analyses. Results Overall, 87 patients received a total of 318 chemotherapy cycles with pegfilgrastim, and 14 patients (16%) experienced FN. In univariate analyses, day 2 pegfilgrastim administration, age of > 65 years, baseline haemoglobin < 12 g/dL, prior history of FN, and presence of recurrent/metastatic disease trended toward an association with FN. Adjustment for these confounding risk factors revealed that day 2 pegfilgrastim administration was associated with a significantly increased risk of FN (odds ratio 11.0, p = 0.009). Conclusion Administrating pegfilgrastim on day 3 or later may prevent FN more effectively among Japanese breast cancer patients receiving intermediate-risk chemotherapies.
KeywordsBreast cancer Febrile neutropenia Intermediate-risk chemotherapies Pegfilgrastim
The authors would like to thank T. Hirano, Dr. K. Enomoto, and Dr. Y. Hara for their valuable contribution to this work.
This study was not financially supported by any third parties.
Conflicts of interest
K Miura received speaker’s fees from Kyowa Hakko Kirin Co. Ltd., which manufactures pegfilgrastim in Japan. M. Takei received research grants from Kyowa Hakko Kirin Co. Ltd. The remaining authors have declared that they have no conflicts of interest.
- 2.National Comprehensive Cancer Network (NCCN); The NCCN clinical practice guidelines in oncology: myeloid growth factors v2. 2017. October 13, 2017.Google Scholar
- 9.Loibl S, Mueller V, von Minckwitz G, Conrad B, Koehne CH, Kremers S, et al. Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Support Care Cancer. 2011;19:1789–95.CrossRefGoogle Scholar